urcosimod
Asset
Agonist of ChemR23 (CMKLR1) resolving ocular neuropathic pain and inflammation
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Inflammation
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Neuropathic corneal pain
Phase 3, globenewswire.com, 6 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets2
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.